Even though the prevalence of diabetes complications has generally trended down in the last 20 years, minorities continue to retain a disproportionate burden for complications related to diabetes.5 Moreover, several novel medications (e.g., glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors, and sodium-glucose transport protein inhibitors) have demonstrated greater efficacy (especially for T2DM) and cardiovascular benefits than traditional anti-diabetes medications. The gene discussed is GLP1R; the disease is diabetes mellitus.